Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
Conclusion: The present analysis shows that additional intracavitary cisplatinfibrin
after eP/D and previous i.v. induction chemotherapy with cisplatin/
pemetrexed can lead to electrolyte disorders and drop in hemoglobin
concentration. However, none of the mentioned laboratory findings had a
clinically significant impact on the patients’ postoperative course.
Keywords: Mesothelioma, chemotherapy, pleurectomy / decortication,
toxicity
POSTER SESSION 3 – P3.03: MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL
CANCER/OTHER THORACIC
MESOTHELIOMA CLINICAL –
WEDNESDAY, DECEMBER 7, 2016
P3.03-045 TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
BEYOND FIRST-LINE AMONG HISPANICS (MESO-CLICAP)
Luis Corrales 1 , Andrés Cardona 2 , Oscar Arrieta 3 , George Oblitas 4 , Leonardo
Rojas 5 , Ludwing Bacon 6 , Claudio Martin 7 , Beatriz Wills 8 , Mauricio Cuello 9 , Luis
Alberto Mas Lopez 10 , Carlos Vargas 2 , Hernan Carranza 2 , Jorge Otero 2 , Maria
Perez 11 , Lisde González 4 , Luis Chirinos 12 , Pilar Archila 13 , Rafael Rosell 14
1 Clinical Oncology Department, Hospital San Juan de Dios (San José, Costa Rica),
San Jose/Costa Rica, 2 Medical Oncology, Clinical and Traslational Oncology
Group, Institute of Oncology, Clínica Del Country, Bogota/Colombia, 3 Thoracic
Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de
Cancerologia, Mexico City/Mexico, 4 Hospital Oncológico Luis Razetti, Caracas,
Venezuela, Caracas/Venezuela, 5 Centro Javeriano de Oncología, Hospital
Universitario San Ignacio, Bogotá/Colombia, 6 Oncology Department, Hospital
Roberto Calderón, Managua, Nicaragua, Managua/Nicaragua, 7 Department of
Clinical Oncology, Instituto Alexander Fleming, Buenos Aires/Argentina, 8 Internal
Medicine Department, Johns Hopkins Hospital, Baltimore, Maryland/United
States of America, 9 Medical Oncology Department, Udelar (Montevideo, Uruguay),
Montevideo/Uruguay, 10 Medical Oncology, Instituto Nacional de Enfermedades
Neoplásicas, Lima/Peru, 11 Medical Oncology, Arsuve, Caracas, Venezuela, Caracas/
Venezuela, 12 Clínica de Prevención Del Cáncer, Caracas, Venezuela, Caracas/
Venezuela, 13 Pathology, Foundation for Clinical and Applied Cancer Research –
Ficmac, Bogota/Colombia, 14 Imppc (Cancer Biology & Precision Medicine Program),
Catalan Institute of Oncology, Badalona, Barcelona/Spain
Background: Platinum/Pemetrexed chemotherapy is standard of care
in first-line (FL) treatment of malignant pleural mesothelioma (MPM).
Different second and third lines regimens are also considered, but the optimal
treatment has not yet been defined. Methods: The aim of this study was to
evaluate clinical outcomes of second (SL) and third line (TL) therapies in a
series of MPMs included in a retrospective multinational database (MeSO-
CLICaP). Clinical records of MPM-patients who received treatment beyond FL
from 2008 to 2016 were reviewed. Study endpoints were response, overallsurvival
(OS), and progression-free-survival (PFS) for SL and TL, stratified
for patient characteristics, FL-outcomes, and type of regimen. Out of 124
patients, 79 received SL/TL and had sufficient clinical data. Results: Of the
124 patients included in the MeSO-CLICaP registry, 79 (64%) received some
treatment after first line. Median age was 59 years (range 33-81), 42 (53%)
were men, 74% were current or former smokers and 77% had a baseline ECOG
0-1. After FL, 57 patients (76%) achieved disease-control (PR 24/32% and SD
33/44%) and 18 had a time-to-progression ≥8 months. Median PFS and OS to
SL were 6.2 (95%CI 4.9-7.4) and 16.1 (95%CI 14.5-17.6) months, respectively.
According to a multivariate analysis, disease control after SL-therapy was
significantly related to pemetrexed-based treatment (OR 2.46; p=0.017) and
FL-TTP≥12 months (OR 3.50; p=0.006). Improved PFS to SL was related to
younger age (